<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=780280282443813&amp;ev=PageView&amp;noscript=1">
search

    Leap Therapeutics, Inc.

    verified_userVerify Profile
    Companies » Health Care » Pharmaceuticals & Biotechnology » Pharmaceuticals

    About Leap Therapeutics, Inc.

    Leap Therapeutics (NASDAQ: LPTX) is focused on developing targeted and immuno-oncology therapeutics. Leap's most advanced clinical candidate, DKN-01, is a humanized monoclonal antibody targeting the Dickkopf-1 (DKK1) protein, a Wnt pathway modulator. DKN-01 is in clinical trials in patients with esophagogastric, hepatobiliary, gynecologic, and prostate cancers. Leap's second clinical candidate, TRX518, is a humanized GITR agonist monoclonal antibody designed to enhance the immune system's anti-tumor response that is in advanced solid tumor studies. Source

    At A Glance

    • CAPITAL RAISE STATUS
      Not Currently Raising
    • FILING TYPE
      Public
    • PLATFORM TYPE
      NASDAQ
    • RAISED AMOUNT
      $X,XXX,XXX
    • PRE-MONEY EVAULATION
      $X,XXX,XXX
    • SIC CODE
      2834
    • NIN CODE
      ####
    • LEADERSHIP
      Chris Mirabelli, Ph.D.
    • FOUNDED
      2011
    • EMPLOYEES
      20
    • SECTOR
      Pharmaceuticals & Biotechnology
    • SUBSECTOR
      Pharmaceuticals

    Company Tags

    No articles found.

    Achieve Life Sciences, Inc.

    Achieve Life Sciences, Inc.

    Achieve is a specialty pharmaceutical company committed to advancing cytisinicline...

    Achieve is a specialty pharmaceutical company c...

    Filing Type:    PU
    Simulations Plus, Inc.

    Simulations Plus, Inc.

    Simulations Plus, Inc. is the leading developer of Absorption, Distribution, Metab...

    Simulations Plus, Inc. is the leading developer...

    Filing Type:    PU
    dna ID, Inc.

    dna ID, Inc.

    The DNA ID platform is a community marketplace for genomics research. The app allo...

    The DNA ID platform is a community marketplace ...

    Amount Raised:    $57,589.00
    Fundraising Status:    EC
    Filing Type:    CF
    Allena Pharmaceuticals, Inc.

    Allena Pharmaceuticals, Inc.

    Allena’s lead product candidate, reloxaliase, is a first-in-class, oral enzyme t...

    Allena’s lead product candidate, reloxaliase,...

    Filing Type:    PU
    Collegium Pharmaceutical, Inc.

    Collegium Pharmaceutical, Inc.

    Collegium Pharmaceutical is a specialty pharmaceutical company committed to being ...

    Collegium Pharmaceutical is a specialty pharmac...

    Filing Type:    PU
    NextCure, Inc.

    NextCure, Inc.

    NextCure is a clinical-stage biopharmaceutical company committed to discovering an...

    NextCure is a clinical-stage biopharmaceutical ...

    Filing Type:    PU
    Moleculin Biotech, Inc.

    Moleculin Biotech, Inc.

    Moleculin Biotech, Inc. is a clinical stage pharmaceutical company focused on the ...

    Moleculin Biotech, Inc. is a clinical stage pha...

    Filing Type:    PU
    IMV Inc.

    IMV Inc.

    IMV Inc. is a clinical stage biopharmaceutical company dedicated to making immunot...

    IMV Inc. is a clinical stage biopharmaceutical ...

    Filing Type:    PU
    Advaxis, Inc.

    Advaxis, Inc.

    Advaxis was founded on the vision that no one should suffer from the burdens of ca...

    Advaxis was founded on the vision that no one s...

    Filing Type:    PU
    ©2026 National Investor Network. All Rights Reserved.